Baxter, Cerus Enter $120 Mil. Platelet Market With EU Intercept Approval
This article was originally published in The Gray Sheet
Executive Summary
Baxter and Cerus plan to launch the first pathogen inactivation system for blood platelets by October, pending widespread blood bank validations and CE mark of a companion device